… Target protein and RNA knockdown of 85–92% was demonstrated in vitro in type 1
human Ewing's sarcoma tumor cell lines with the optimal bi-shRNA EWS/FLI1 plasmid. This …

… STMN1) that cleaves STMN1 mRNA was evaluated in melanoma and osteosarcoma (39)
and in patients with superficial advanced refractory cancer (40) … In the current study, we have …

… and will experience relapse or refractory progression [1, 21-24]. … Study e204 was designed
to follow body weight and tumor … bi-shRNA plasmid/LPX delivery vehicle targeting Stathmin 1 (…

… Meanwhile, more than 2,000 clinical trials of NA therapies are underway, and more NA
drugs are in the pipeline of biopharmaceutical companies. These data show us that the NA …

… Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related …
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients …

… Stathmin (STMN) plays a vital role in maintaining the … ranked tumor cells with obvious atypia
in tumor tissues with big … superficial advanced refractory cancer in phase I clinical trial and …

… study has focused on the significance of stathmin expression in melanoma 6 . In this study,
the authors found that (a) stathmin … (b) the level of stathmin expression is negatively correlated …

… STMN1 is a cytosolic protein with major promitotic responsibility that is … cancer cell survival
and proliferation [33], [34], [35]. Their Phase I study in superficial advanced refractory cancer …

… targeting, and miRNAs to silence STMN1 might be effective strategies to inhibit cell
division [Citation79–81]. Besides, a recent study showed that PAI-1 participates in the p53–miR-34a …

… In a Phase I study of OX40 agonist MOXR0916 administered … events (AEs) were Grade
1–2 and related to MOXR0916 … Phase 1 trial of Bi-shRNA STMN1 BIV in refractory cancer. …